NATURES SUNSHINE PRODUCTS INC - Common Stock (NATR)

CUSIP: 639027101

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock
Total 13F shares
14,286,419
Total 13F value
$211,274,654
Holder snapshot 6 signals
Share change
-918,827
SEC-reported price per share
$14.79
Number of holders
114
Value change
-$12,667,158
Number of buys
78
Number of sells
25
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
17,654,067

Security key

639027101

Report period

Q2 2025

Institutions

114

Top holders

10

NATR full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 NATURES SUNSHINE PRODUCTS INC SEC filings NATURES SUNSHINE PRODUCTS INC company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of NATR - NATURES SUNSHINE PRODUCTS INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Shanghai Fosun Pharmaceut...
Disclosed value leader
Fosun International Ltd
Comparable rows
15/15
Latest evidence
25 Jun 2025
13D/G 3/4/5 13F Lead comparable stake: 0.35% 13D/G row: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Showing 1-6 of 15 holder rows.

Quick read

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. leads the comparable SEC ownership view at 0.35%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s linked filing trail.
Comparable ownership Top 5
Shanghai Fosun Pharmaceutical (Gr... 0.35%
Fosun Pharma USA Inc. 16%
Fosun International Ltd 17%
WYNNEFIELD CAPITAL INC 14%
PRESCOTT GROUP CAPITAL MANAGEMENT... 10%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13D/G 3/4/5
10%+ Owner
13D/G 3/4/5
0.35%
$735,354
64,167 shares
 -$32,713,796 25 Jun 2025
Fosun Pharma USA Inc.
3/4/5
10%+ Owner
3/4/5
16%
$32,713,796
2,854,607 shares
 — 05 Jun 2025
Fosun International Ltd
13F
Company
13F
17%
$36,630,614
2,918,774 shares
 — 31 Mar 2025
WYNNEFIELD CAPITAL INC
13F
Company
13F
14%
$31,044,759
2,473,686 shares
 — 31 Mar 2025
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
13F
Company
13F
10%
$22,377,868
1,783,097 shares
 — 31 Mar 2025
DIMENSIONAL FUND ADVISORS LP
13F
Company
13F
5%
$11,025,767
878,549 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
114
Shares
14,286,419
Rows available
114
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2026 Across Filers

Q1 2026 holders
152
Q2 2025 holders
114
Holder diff
-38
Investor Q1 2026 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2026 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .